The combination of insider selling and a recent equity offering warrants close monitoring of further insider activity and upcoming clinical catalysts. The positive regulatory news for AMT-130 may support the stock, but the insider sales suggest caution near term. Watch for additional Form 4 filings and any updates on the BLA submission timeline.
Drug in focus
QURE drug pipeline →AMT-130
▲ Bullish Named in this insider cluster- Impact
- Phase
- Phase 1/2 (pivotal for accelerated approval)
- Time to market
- BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
- Next catalyst
- None dated
What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jul 6 $41.81entry
- T+1 · 4mo ago −1.08%α −1.95% · $41.36
- T+5 · 4mo ago +6.39%α +5.46% · $44.48
- T+20 · 4mo ago +0.91%α +1.32% · $42.19
- T+60 · due 7w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure's CEO and CMO sold ~$2.9M in open-market sales within days of a $225M public offering. The sales are modest relative to market cap (0.1%) but notable given the insider seniority and the proximity to the capital raise. The company recently announced FDA alignment for accelerated approval of its lead gene therapy, which tempers the bearish signal.
Key Financial Metrics
Key Facts
- CEO Matthew Kapusta sold 28,700 shares at $50.02 for ~$1.44M on June 25, 2026.
- CMO Walid Abi-Saab sold a total of ~31,434 shares across three trades (June 26 & 30) for ~$1.46M.
- The insider selling cluster follows a $225M underwritten public offering priced at $45.50/share on June 23-24.
- uniQure recently received FDA alignment to use Phase I/II data as primary basis for a BLA submission under accelerated approval for AMT-130.
- Total insider sales represent approximately 0.1% of uniQure's $2.8B market cap.
Financial Impact
CEO and CMO sold ~$2.9M in open-market sales, representing ~0.1% of market cap.
Risk Factors
- Further insider selling could signal lack of confidence.
- Dilution from the $225M offering may pressure the stock.
- Execution risk for AMT-130 BLA submission and commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QURE-1783026103175 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers